


PHARMACEUTICAL 2018

Epizyme Inc. Rank 167 of 349







PHARMACEUTICAL 2018

Epizyme Inc. Rank 167 of 349



The relative strengths and weaknesses of Epizyme Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epizyme Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 306% points. The greatest weakness of Epizyme Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -162%, being 116% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	285,804
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,664
Liabilities, Non-Current	0
Other Assets	1,028
Other Compr. Net Income	57
Other Expenses	-336
Other Liabilities	0
Other Net Income	12,197
Property and Equipment	2,527
Research and Development	109,661
Revenues	0
Selling, General and Administrative Expense	37,181

Output Variable	Value in 1000 USD
Assets	289,359
Liabilities	24,664
Expenses	146,506
Stockholders Equity	264,695
Net Income	-134,309
Comprehensive Net Income	-134,280
Economic Capital Ratio	-162%